August 2024- Abbott announced a unique global partnership with Medtronic to collaborate on an integrated continuous glucose monitoring (CGM) system based on Abbott’s FreeStyle Libre technology that will connect with Medtronic’s automated insulin delivery (AID) and smart insulin pen systems.
The integration of Abbott’s CGM sensor with Medtronic’s AID algorithms will enable automatic adjustments of insulin to keep glucose in range. Abbott will develop the CGM sensor, and Medtronic will sell it, designed to work exclusively with Medtronic devices.
AID systems improve health outcomes while reducing the burden of constant decision-making for people with diabetes who use intensive insulin as part of their overall therapy. AID systems can benefit people with both Type 1 and Type 2 diabetes who require multiple daily injections of rapid-acting insulin, currently estimated at more than 11 million people globally.
Also Read: AbbVie Completes Acquisition of Cerevel Therapeutics
“Libre technology has set the standard for accurate, accessible, easy-to-use and reliable continuous glucose monitoring. Connecting this CGM built for Medtronic’s insulin delivery systems and algorithms makes it easier for people to spend less time thinking about their diabetes and more time living” said Jared Watkin, executive vice president of Abbott’s diabetes care business
“Our partnership with Abbott allows us to expand access to our advanced automated insulin delivery and smart MDI systems that deliver best-in-class outcomes with the most widely used CGM in the world,” said Que Dallara, executive vice president and president, Medtronic Diabetes.
